1. Home
  2. MCHX vs LPCN Comparison

MCHX vs LPCN Comparison

Compare MCHX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

HOLD

Current Price

$1.56

Market Cap

66.3M

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$7.58

Market Cap

61.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCHX
LPCN
Founded
2003
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.3M
61.8M
IPO Year
2003
2011

Fundamental Metrics

Financial Performance
Metric
MCHX
LPCN
Price
$1.56
$7.58
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
12.3K
96.6K
Earning Date
03-25-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
$90,291,000.00
$1,976,677.00
Revenue This Year
$9.12
N/A
Revenue Next Year
N/A
$74.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$2.52
52 Week High
$2.30
$12.37

Technical Indicators

Market Signals
Indicator
MCHX
LPCN
Relative Strength Index (RSI) 52.99 46.08
Support Level $1.35 $2.87
Resistance Level $1.76 $8.35
Average True Range (ATR) 0.09 0.68
MACD 0.02 -0.00
Stochastic Oscillator 65.84 29.30

Price Performance

Historical Comparison
MCHX
LPCN

About MCHX Marchex Inc. Class B

Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: